{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:19:48Z","timestamp":1783423188266,"version":"3.54.6"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32171289"],"award-info":[{"award-number":["32171289"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31970619"],"award-info":[{"award-number":["31970619"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL141336"],"award-info":[{"award-number":["R01 HL141336"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA248149"],"award-info":[{"award-number":["R01 CA248149"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["ACS RSG-19-036001-LIB"],"award-info":[{"award-number":["ACS RSG-19-036001-LIB"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2024,7,22]]},"DOI":"10.1038\/s41416-024-02729-0","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T17:38:51Z","timestamp":1716917931000},"page":"231-242","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes"],"prefix":"10.1038","volume":"131","author":[{"given":"Fangliang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6473-2046","authenticated-orcid":false,"given":"Ruiqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huichao","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6748-9416","authenticated-orcid":false,"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"2729_CR1","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nrc2047","volume":"7","author":"SJ Corey","year":"2007","unstructured":"Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer. 2007;7:118\u201329.","journal-title":"Nat Rev Cancer"},{"key":"2729_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64\u201369.","journal-title":"Nature"},{"key":"2729_CR3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nrc.2016.51","volume":"16","author":"H Dvinge","year":"2016","unstructured":"Dvinge H, Kim E, Abdel-Wahab O, Bradley RK. RNA splicing factors as oncoproteins and tumour suppressors. Nat Rev Cancer. 2016;16:413\u201330.","journal-title":"Nat Rev Cancer"},{"key":"2729_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jbior.2016.08.001","volume":"63","author":"A Pellagatti","year":"2017","unstructured":"Pellagatti A, Boultwood J. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications. Adv Biol Regul. 2017;63:59\u201370.","journal-title":"Adv Biol Regul"},{"key":"2729_CR5","first-page":"6239","volume":"118","author":"L Malcovati","year":"2011","unstructured":"Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms. Blood J Am Soc Hematol. 2011;118:6239\u201346.","journal-title":"Blood J Am Soc Hematol"},{"key":"2729_CR6","first-page":"3578","volume":"119","author":"F Thol","year":"2012","unstructured":"Thol F, Kade S, Schlarmann C, L\u00f6ffeld P, Morgan M, Krauter J, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood J Am Soc Hematol. 2012;119:3578\u201384.","journal-title":"Blood J Am Soc Hematol"},{"key":"2729_CR7","first-page":"3203","volume":"119","author":"H Makishima","year":"2012","unstructured":"Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Abu Kar S, Jerez A, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood J Am Soc Hematol. 2012;119:3203\u201310.","journal-title":"Blood J Am Soc Hematol"},{"key":"2729_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jbior.2013.09.005","volume":"54","author":"J Boultwood","year":"2014","unstructured":"Boultwood J, Dolatshad H, Varanasi SS, Yip BH, Pellagatti A. The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes. Adv Biol Regul. 2014;54:153\u201361.","journal-title":"Adv Biol Regul"},{"key":"2729_CR9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1158\/2159-8290.CD-13-0330","volume":"3","author":"SJ Furney","year":"2013","unstructured":"Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, Desjardins L, et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 2013;3:1122\u20139.","journal-title":"Cancer Discov"},{"key":"2729_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature11547","volume":"491","author":"AV Biankin","year":"2012","unstructured":"Biankin AV, Waddell N, Kassahn KS, Gingras M-C, Muthuswamy LB, Johns AL, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491:399\u2013405.","journal-title":"Nature"},{"key":"2729_CR11","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.cell.2012.08.029","volume":"150","author":"M Imielinski","year":"2012","unstructured":"Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150:1107\u201320.","journal-title":"Cell"},{"key":"2729_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/ng.2523","volume":"45","author":"JW Harbour","year":"2013","unstructured":"Harbour JW, Roberson ED, Anbunathan H, Onken MD, Worley LA, Bowcock AM. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet. 2013;45:133\u20135.","journal-title":"Nat Genet"},{"key":"2729_CR13","first-page":"1235","volume":"67","author":"A Martin","year":"2013","unstructured":"Martin A, Orgogozo V. The loci of repeated evolution: a catalog of genetic hotspots of phenotypic variation. Evolution. 2013;67:1235\u201350.","journal-title":"Evolution"},{"key":"2729_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature11143","volume":"486","author":"MJ Ellis","year":"2012","unstructured":"Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486:353\u201360.","journal-title":"Nature"},{"key":"2729_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","volume":"27","author":"E Kim","year":"2015","unstructured":"Kim E, Ilagan JO, Liang Y, Daubner GM, Lee SC-W, Ramakrishnan A, et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell. 2015;27:617\u201330.","journal-title":"Cancer Cell"},{"key":"2729_CR16","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ccell.2016.08.006","volume":"30","author":"E Obeng","year":"2016","unstructured":"Obeng E, Chappell R, Seiler M, Chen M, Campagna D, Schmidt P, et al. Physiologic expression of Sf3b1K700E causes impaired erythropoiesis, aberrant splicing, and sensitivity to therapeutic spliceosome modulation. Cancer Cell. 2016;30:404\u201317.","journal-title":"Cancer Cell"},{"key":"2729_CR17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ccell.2015.04.008","volume":"27","author":"CL Shirai","year":"2015","unstructured":"Shirai CL, Ley JN, White BS, Kim S, Tibbitts J, Shao J, et al. Mutant U2AF1 expression alters hematopoiesis and pre-mRNA splicing in vivo. Cancer Cell. 2015;27:631\u201343.","journal-title":"Cancer Cell"},{"key":"2729_CR18","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/nm.4097","volume":"22","author":"SC-W Lee","year":"2016","unstructured":"Lee SC-W, Dvinge H, Kim E, Cho H, Micol J-B, Chung YR, et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med. 2016;22:672\u20138.","journal-title":"Nat Med"},{"key":"2729_CR19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nm.4493","volume":"24","author":"M Seiler","year":"2018","unstructured":"Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat Med. 2018;24:497\u2013504.","journal-title":"Nat Med"},{"key":"2729_CR20","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nrd3823","volume":"11","author":"S Bonnal","year":"2012","unstructured":"Bonnal S, Vigevani L, Valc\u00e1rcel J. The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov. 2012;11:847\u201359.","journal-title":"Nat Rev Drug Discov"},{"key":"2729_CR21","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.1038\/s41375-021-01328-9","volume":"35","author":"DP Steensma","year":"2021","unstructured":"Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, et al. Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021;35:3542\u201350.","journal-title":"Leukemia"},{"key":"2729_CR22","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.molcel.2017.12.029","volume":"69","author":"L Chen","year":"2018","unstructured":"Chen L, Chen J-Y, Huang Y-J, Gu Y, Qiu J, Qian H, et al. The augmented R-loop is a unifying mechanism for myelodysplastic syndromes induced by high-risk splicing factor mutations. Mol Cell. 2018;69:412\u201325.e416.","journal-title":"Mol Cell"},{"key":"2729_CR23","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s10637-013-0046-5","volume":"32","author":"D Hong","year":"2014","unstructured":"Hong D, Kurzrock R, Naing A, Wheler J, Falchook G, Schiffman J, et al. A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Investig N Drugs. 2014;32:436\u201344.","journal-title":"Investig N Drugs"},{"key":"2729_CR24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1101\/gr.181016.114","volume":"25","author":"JO Ilagan","year":"2015","unstructured":"Ilagan JO, Ramakrishnan A, Hayes B, Murphy ME, Zebari AS, Bradley P, et al. U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res. 2015;25:14\u201326.","journal-title":"Genome Res"},{"key":"2729_CR25","first-page":"1225","volume":"132","author":"A Pellagatti","year":"2018","unstructured":"Pellagatti A, Armstrong RN, Steeples V, Sharma E, Repapi E, Singh S, et al. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes\/pathways and clinical associations. Blood J Am Soc Hematol. 2018;132:1225\u201340.","journal-title":"Blood J Am Soc Hematol"},{"key":"2729_CR26","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.cell.2013.04.028","volume":"153","author":"X Ji","year":"2013","unstructured":"Ji X, Zhou Y, Pandit S, Huang J, Li H, Lin CY, et al. SR proteins collaborate with 7SK and promoter-associated nascent RNA to release paused polymerase. Cell. 2013;153:855\u201368. https:\/\/doi.org\/10.1016\/j.cell.2013.04.028.","journal-title":"Cell"},{"key":"2729_CR27","doi-asserted-by":"crossref","unstructured":"Boddu PC, Gupta AK, Roy R, Avalos BDLP, Olazabal-Herrero A, Neuenkirchen N, et al. Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape. Molecular Cell. 2024;84:1475\u201395.","DOI":"10.1016\/j.molcel.2024.02.032"},{"key":"2729_CR28","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.cell.2019.08.055","volume":"179","author":"T Garc\u00eda-Muse","year":"2019","unstructured":"Garc\u00eda-Muse T, Aguilera A. R loops: from physiological to pathological roles. Cell. 2019;179:604\u201318.","journal-title":"Cell"},{"key":"2729_CR29","doi-asserted-by":"publisher","first-page":"e47250","DOI":"10.15252\/embr.201847250","volume":"20","author":"S Barroso","year":"2019","unstructured":"Barroso S, Herrera\u2010Moyano E, Mu\u00f1oz S, Garc\u00eda\u2010Rubio M, G\u00f3mez\u2010Gonz\u00e1lez B, Aguilera A. The DNA damage response acts as a safeguard against harmful DNA\u2013RNA hybrids of different origins. EMBO Rep. 2019;20:e47250.","journal-title":"EMBO Rep"},{"key":"2729_CR30","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.molcel.2019.01.024","volume":"73","author":"MP Crossley","year":"2019","unstructured":"Crossley MP, Bocek M, Cimprich KA. R-loops as cellular regulators and genomic threats. Mol Cell. 2019;73:398\u2013411.","journal-title":"Mol Cell"},{"key":"2729_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.dnarep.2018.08.009","volume":"71","author":"BP Belotserkovskii","year":"2018","unstructured":"Belotserkovskii BP, Tornaletti S, D\u2019Souza AD, Hanawalt PC. R-loop generation during transcription: formation, processing and cellular outcomes. DNA repair. 2018;71:69\u201381.","journal-title":"DNA repair"},{"key":"2729_CR32","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.3324\/haematol.2020.254193","volume":"106","author":"J Flach","year":"2021","unstructured":"Flach J, Jann J-C, Knaflic A, Riabov V, Streuer A, Altrock E, et al. Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations. Haematologica. 2021;106:2906.","journal-title":"Haematologica"},{"key":"2729_CR33","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1158\/0008-5472.CAN-17-3970","volume":"78","author":"HD Nguyen","year":"2018","unstructured":"Nguyen HD, Leong WY, Li W, Reddy PN, Sullivan JD, Walter MJ, et al. Spliceosome mutations induce R loop-associated sensitivity to ATR inhibition in myelodysplastic syndromes. Cancer Res. 2018;78:5363\u201374.","journal-title":"Cancer Res"},{"key":"2729_CR34","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1038\/s41375-020-0753-9","volume":"34","author":"S Singh","year":"2020","unstructured":"Singh S, Ahmed D, Dolatshad H, Tatwavedi D, Schulze U, Sanchi A, et al. SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications. Leukemia. 2020;34:2525\u201330.","journal-title":"Leukemia"},{"key":"2729_CR35","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.molcel.2017.01.029","volume":"65","author":"HD Nguyen","year":"2017","unstructured":"Nguyen HD, Yadav T, Giri S, Saez B, Graubert TA, Zou L. Functions of replication protein A as a sensor of R loops and a regulator of RNaseH1. Mol Cell. 2017;65:832\u201347.e834.","journal-title":"Mol Cell"},{"key":"2729_CR36","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1182\/bloodadvances.2021004571","volume":"6","author":"JJ Xu","year":"2022","unstructured":"Xu JJ, Chalk AM, Nikolic I, Simpson KJ, Smeets MF, Walkley CR. Genome-wide screening identifies cell-cycle control as a synthetic lethal pathway with SRSF2P95H mutation. Blood Adv. 2022;6:2092\u2013106.","journal-title":"Blood Adv"},{"key":"2729_CR37","doi-asserted-by":"crossref","unstructured":"Foote KM, Nissink JWM, McGuire T, Turner P, Guichard S, Yates JWT, et al. Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent. Journal of Medicinal Chemistry. 2018;61:9889\u20139907.","DOI":"10.1021\/acs.jmedchem.8b01187"},{"key":"2729_CR38","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1182\/blood-2021-147960","volume":"138","author":"S Eldfors","year":"2021","unstructured":"Eldfors S, Rai S, Sharma V, Gilbert AN, Porkka K, Graubert TA. ATR\/CHK1\/WEE1 dependency in SRSF2-mutated MDS\/AML. Blood. 2021;138:3661.","journal-title":"Blood"},{"key":"2729_CR39","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3390\/cancers14040953","volume":"14","author":"F Martorana","year":"2022","unstructured":"Martorana F, Da Silva LA, Sessa C, Colombo I. Everything comes with a price: the toxicity profile of DNA-damage response targeting agents. Cancers. 2022;14:953.","journal-title":"Cancers"},{"key":"2729_CR40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.cancergen.2020.12.002","volume":"252","author":"LC de Almeida","year":"2021","unstructured":"de Almeida LC, Calil FA, Machado-Neto JA, Costa-Lotufo LV. DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy. Cancer Genet. 2021;252:6\u201324.","journal-title":"Cancer Genet"},{"key":"2729_CR41","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1158\/0008-5472.CAN-21-4339","volume":"82","author":"MJ Llorca-Cardenosa","year":"2022","unstructured":"Llorca-Cardenosa MJ, Aronson LI, Krastev DB, Nieminuszczy J, Alexander J, Song F, et al. SMG8\/SMG9 heterodimer loss modulates SMG1 kinase to drive ATR inhibitor resistance. Cancer Res. 2022;82:3962\u201373.","journal-title":"Cancer Res"},{"key":"2729_CR42","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.1158\/0008-5472.CAN-21-4335","volume":"82","author":"PC O\u2019Leary","year":"2022","unstructured":"O\u2019Leary PC, Chen H, Doruk YU, Williamson T, Polacco B, McNeal AS, et al. Resistance to ATR inhibitors is mediated by loss of the nonsense-mediated decay factor UPF2. Cancer Res. 2022;82:3950\u201361.","journal-title":"Cancer Res"},{"key":"2729_CR43","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nature08467","volume":"461","author":"SP Jackson","year":"2009","unstructured":"Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071\u20138.","journal-title":"Nature"},{"key":"2729_CR44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","volume":"23","author":"FJ Groelly","year":"2023","unstructured":"Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M. Targeting DNA damage response pathways in cancer. Nat Rev Cancer. 2023;23:78\u201394.","journal-title":"Nat Rev Cancer"},{"key":"2729_CR45","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3390\/cancers12041050","volume":"12","author":"JF Alhmoud","year":"2020","unstructured":"Alhmoud JF, Woolley JF, Al Moustafa A-E, Malki MI. DNA damage\/repair management in cancers. Cancers. 2020;12:1050.","journal-title":"Cancers"},{"key":"2729_CR46","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1101\/gr.237362.118","volume":"28","author":"IX Wang","year":"2018","unstructured":"Wang IX, Grunseich C, Fox J, Burdick J, Zhu Z, Ravazian N, et al. Human proteins that interact with RNA\/DNA hybrids. Genome Res. 2018;28:1405\u201314.","journal-title":"Genome Res"},{"key":"2729_CR47","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1016\/j.celrep.2018.04.025","volume":"23","author":"A Cristini","year":"2018","unstructured":"Cristini A, Groh M, Kristiansen MS, Gromak N. RNA\/DNA hybrid interactome identifies DXH9 as a molecular player in transcriptional termination and R-loop-associated DNA damage. Cell Rep. 2018;23:1891\u2013905.","journal-title":"Cell Rep"},{"key":"2729_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27722-6","volume":"13","author":"Q Yan","year":"2022","unstructured":"Yan Q, Wulfridge P, Doherty J, Fernandez-Luna JL, Real PJ, Tang H-Y, et al. Proximity labeling identifies a repertoire of site-specific R-loop modulators. Nat Commun. 2022;13:53.","journal-title":"Nat Commun"},{"key":"2729_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111089","volume":"40","author":"W-L Lin","year":"2022","unstructured":"Lin W-L, Chen J-K, Wen X, He W, Zarceno GA, Chen Y, et al. DDX18 prevents R-loop-induced DNA damage and genome instability via PARP-1. Cell Rep. 2022;40:111089.","journal-title":"Cell Rep"},{"key":"2729_CR50","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1093\/nar\/gkad066","volume":"51","author":"N Laspata","year":"2023","unstructured":"Laspata N, Kaur P, Mersaoui SY, Muoio D, Liu ZS, Bannister MH, et al. PARP1 associates with R-loops to promote their resolution and genome stability. Nucleic Acids Res. 2023;51:2215\u201337.","journal-title":"Nucleic Acids Res"},{"key":"2729_CR51","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nmeth1104-163","volume":"1","author":"PJ Paddison","year":"2004","unstructured":"Paddison PJ, Cleary M, Silva JM, Chang K, Sheth N, Sachidanandam R, et al. Cloning of short hairpin RNAs for gene knockdown in mammalian cells. Nat Methods. 2004;1:163\u20137.","journal-title":"Nat Methods"},{"key":"2729_CR52","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1200\/EDBK_238473","volume":"39","author":"TA Yap","year":"2019","unstructured":"Yap TA, Plummer R, Azad NS, Helleday T. The DNA damaging revolution: PARP inhibitors and beyond. Am Soc Clin Oncol Educ Book. 2019;39:185\u201395.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2729_CR53","doi-asserted-by":"publisher","first-page":"9575","DOI":"10.1021\/acs.jmedchem.6b00055","volume":"59","author":"Y-Q Wang","year":"2016","unstructured":"Wang Y-Q, Wang P-Y, Wang Y-T, Yang G-F, Zhang A, Miao Z-H. An update on poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors: opportunities and challenges in cancer therapy. J Med Chem. 2016;59:9575\u201398.","journal-title":"J Med Chem"},{"key":"2729_CR54","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/1440-1681.13646","volume":"49","author":"C Chen","year":"2022","unstructured":"Chen C, Zhou P, Zhang Z, Liu Y. U2AF1 mutation connects DNA damage to the alternative splicing of RAD51 in lung adenocarcinomas. Clin Exp Pharmacol Physiol. 2022;49:740\u20137.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2729_CR55","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41568-022-00541-7","volume":"23","author":"RK Bradley","year":"2023","unstructured":"Bradley RK, Anczuk\u00f3w O. RNA splicing dysregulation and the hallmarks of cancer. Nat Rev Cancer. 2023;23:135\u201355.","journal-title":"Nat Rev Cancer"},{"key":"2729_CR56","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41571-020-0350-x","volume":"17","author":"SC Bonnal","year":"2020","unstructured":"Bonnal SC, L\u00f3pez-Oreja I, Valc\u00e1rcel J. Roles and mechanisms of alternative splicing in cancer\u2014implications for care. Nat Rev Clin Oncol. 2020;17:457\u201374.","journal-title":"Nat Rev Clin Oncol"},{"key":"2729_CR57","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1182\/blood-2019-126981","volume":"134","author":"S Singh","year":"2019","unstructured":"Singh S, Ahmed D, Dolatshad H, Tatwavedi D, Schulze U, Sanchi A, et al. The SF3B1 K700E mutation induces R-loop accumulation and associated DNA damage. Blood. 2019;134:4219.","journal-title":"Blood"},{"key":"2729_CR58","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/s41588-023-01460-5","volume":"55","author":"P Bland","year":"2023","unstructured":"Bland P, Saville H, Wai PT, Curnow L, Muirhead G, Nieminuszczy J, et al. SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response. Nat Genet. 2023;55:1311\u201323.","journal-title":"Nat Genet"},{"key":"2729_CR59","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/cpr.12268","volume":"49","author":"T Jubin","year":"2016","unstructured":"Jubin T, Kadam A, Jariwala M, Bhatt S, Sutariya S, Gani A, et al. The PARP family: insights into functional aspects of poly (ADP\u2010ribose) polymerase\u20101 in cell growth and survival. Cell Prolif. 2016;49:421\u201337.","journal-title":"Cell Prolif"},{"key":"2729_CR60","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.cmet.2012.06.016","volume":"16","author":"P Bai","year":"2012","unstructured":"Bai P, Cant\u00f3 C. The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. Cell Metab. 2012;16:290\u20135.","journal-title":"Cell Metab"},{"key":"2729_CR61","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.molcel.2018.06.004","volume":"71","author":"H Hanzlikova","year":"2018","unstructured":"Hanzlikova H, Kalasova I, Demin AA, Pennicott LE, Cihlarova Z, Caldecott KW. The importance of poly (ADP-ribose) polymerase as a sensor of unligated Okazaki fragments during DNA replication. Mol Cell. 2018;71:319\u201331.e313.","journal-title":"Mol Cell"},{"key":"2729_CR62","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","volume":"18","author":"A Ray Chaudhuri","year":"2017","unstructured":"Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18:610\u201321.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2729_CR63","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1016\/j.molcel.2022.04.031","volume":"82","author":"J Zhao","year":"2022","unstructured":"Zhao J, Tian S, Guo Q, Bao K, Yu G, Wang X, et al. A PARylation-phosphorylation cascade promotes TOPBP1 loading and RPA-RAD51 exchange in homologous recombination. Mol Cell. 2022;82:2571\u201387.e2579.","journal-title":"Mol Cell"},{"key":"2729_CR64","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/356356a0","volume":"356","author":"MS Satoh","year":"1992","unstructured":"Satoh MS, Lindahl T. Role of poly (ADP-ribose) formation in DNA repair. Nature. 1992;356:356\u20138.","journal-title":"Nature"},{"key":"2729_CR65","doi-asserted-by":"publisher","first-page":"11600","DOI":"10.1093\/nar\/gkac948","volume":"50","author":"T Mosler","year":"2022","unstructured":"Mosler T, Baymaz HI, Gr\u00e4f JF, Mikicic I, Blattner G, Bartlett E, et al. PARP1 proximity proteomics reveals interaction partners at stressed replication forks. Nucleic Acids Res. 2022;50:11600\u201318.","journal-title":"Nucleic Acids Res"},{"key":"2729_CR66","doi-asserted-by":"publisher","first-page":"103132","DOI":"10.1016\/j.dnarep.2021.103132","volume":"104","author":"BJ Ye","year":"2021","unstructured":"Ye BJ, Kang HJ, Lee-Kwon W, Kwon HM, Choi SY. PARP1-mediated PARylation of TonEBP prevents R-loop\u2013associated DNA damage. DNA Repair. 2021;104:103132.","journal-title":"DNA Repair"},{"key":"2729_CR67","doi-asserted-by":"publisher","first-page":"D303","DOI":"10.1093\/nar\/gkab1103","volume":"50","author":"R Lin","year":"2022","unstructured":"Lin R, Zhong X, Zhou Y, Geng H, Hu Q, Huang Z, et al. R-loopBase: a knowledgebase for genome-wide R-loop formation and regulation. Nucleic Acids Res. 2022;50:D303\u201315.","journal-title":"Nucleic Acids Res"},{"key":"2729_CR68","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40268-020-00301-8","volume":"20","author":"S Boussios","year":"2020","unstructured":"Boussios S, Abson C, Moschetta M, Rassy E, Karathanasi A, Bhat T, et al. Poly (ADP-Ribose) polymerase inhibitors: talazoparib in ovarian cancer and beyond. Drugs RD. 2020;20:55\u201373.","journal-title":"Drugs RD"},{"key":"2729_CR69","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1158\/2159-8290.CD-16-1250","volume":"7","author":"J de Bono","year":"2017","unstructured":"de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, et al. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1\/2 mutations and selected sporadic cancerstalazoparib in patients with advanced\/recurrent solid tumors. Cancer Discov. 2017;7:620\u20139.","journal-title":"Cancer Discov"},{"key":"2729_CR70","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon\u00e7alves A, Lee K-H, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New Engl J Med. 2018;379:753\u201363.","journal-title":"New Engl J Med"},{"key":"2729_CR71","unstructured":"Mufti G, Estey E, Popat R, Mattison R, Menne T, Azar J, et al. Results of a phase 1 study of BMN 673, a potent and specific PARP-1\/2 inhibitor, in patients with advanced hematological malignancies. In: Proceedings of the 19th Congress of the European Hematology Association, Milan, Italy, 33\u201334 June 2014."},{"key":"2729_CR72","doi-asserted-by":"publisher","first-page":"zcac042","DOI":"10.1093\/narcan\/zcac042","volume":"4","author":"LM Jackson","year":"2022","unstructured":"Jackson LM, Moldovan G-L. Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment. NAR Cancer. 2022;4:zcac042.","journal-title":"NAR Cancer"},{"key":"2729_CR73","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ygyno.2017.03.236","volume":"145","author":"E George","year":"2017","unstructured":"George E, Kim H, Ragland R, Rafail S, Zhang R, Krepler C, et al. Targeting the ATR-Chk1 axis with PARP inhibition results in tumor regression in BRCA mutant models. Gynecol Oncol. 2017;145:100.","journal-title":"Gynecol Oncol"},{"key":"2729_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.09.003","volume":"71","author":"B Haynes","year":"2018","unstructured":"Haynes B, Murai J, Lee J-M. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. Cancer Treat Rev. 2018;71:1\u20137.","journal-title":"Cancer Treat Rev"},{"key":"2729_CR75","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1158\/1535-7163.MCT-12-0950","volume":"12","author":"A Min","year":"2013","unstructured":"Min A, Im S-A, Yoon Y-K, Song S-H, Nam H-J, Hur H-S, et al. RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib sensitivity in RAD51C-deficient cancer cells. Mol Cancer Ther. 2013;12:865\u201377.","journal-title":"Mol Cancer Ther"},{"key":"2729_CR76","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1182\/bloodadvances.2021004638","volume":"5","author":"C-N Kontandreopoulou","year":"2021","unstructured":"Kontandreopoulou C-N, Diamantopoulos PT, Tiblalexi D, Giannakopoulou N, Viniou N-A. PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome. Blood Adv. 2021;5:4794\u2013805.","journal-title":"Blood Adv"},{"key":"2729_CR77","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","volume":"19","author":"NJ Curtin","year":"2020","unstructured":"Curtin NJ, Szabo C. Poly (ADP-ribose) polymerase inhibition: past, present and future. Nat Rev Drug Discov. 2020;19:711\u201336.","journal-title":"Nat Rev Drug Discov"},{"key":"2729_CR78","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s12276-021-00557-3","volume":"53","author":"D-S Kim","year":"2021","unstructured":"Kim D-S, Camacho CV, Kraus WL. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. Exp Mol Med. 2021;53:42\u201351.","journal-title":"Exp Mol Med"},{"key":"2729_CR79","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/GCO.0000000000000678","volume":"33","author":"E Hinchcliff","year":"2021","unstructured":"Hinchcliff E, Chelariu-Raicu A, Westin SN. Current and future landscape of PARPi resistance. Curr Opin Obstet Gynecol. 2021;33:19.","journal-title":"Curr Opin Obstet Gynecol"},{"key":"2729_CR80","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","volume":"30","author":"J Mateo","year":"2019","unstructured":"Mateo J, Lord C, Serra V, Tutt A, Balma\u00f1a J, Castroviejo-Bermejo M, et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol. 2019;30:1437\u201347.","journal-title":"Ann Oncol"},{"key":"2729_CR81","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41568-021-00386-6","volume":"21","author":"RM Chabanon","year":"2021","unstructured":"Chabanon RM, Rouanne M, Lord CJ, Soria J-C, Pasero P, Postel-Vinay S. Targeting the DNA damage response in immuno-oncology: developments and opportunities. Nat Rev Cancer. 2021;21:701\u201317.","journal-title":"Nat Rev Cancer"},{"key":"2729_CR82","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-022-01228-0","volume":"15","author":"A Padella","year":"2022","unstructured":"Padella A, Ghelli Luserna Di Ror\u00e0 A, Marconi G, Ghetti M, Martinelli G, Simonetti G. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies. J Hematol Oncol. 2022;15:10.","journal-title":"J Hematol Oncol"},{"key":"2729_CR83","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1158\/1078-0432.CCR-16-1274","volume":"23","author":"KW Pratz","year":"2017","unstructured":"Pratz KW, Rudek MA, Gojo I, Litzow MR, McDevitt MA, Ji J, et al. A phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms, and chronic myelomonocytic leukemiatopotecan carboplatin and PARPi veliparib in leukemia. Clin Cancer Res. 2017;23:899\u2013907.","journal-title":"Clin Cancer Res"},{"key":"2729_CR84","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","volume":"21","author":"L Li","year":"2012","unstructured":"Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T, et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell. 2012;21:266\u201381.","journal-title":"Cancer Cell"},{"key":"2729_CR85","first-page":"548","volume":"134","author":"X He","year":"2019","unstructured":"He X, Zhu Y, Lin Y-C, Li M, Du J, Dong H, et al. PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD+ acute myeloid leukemia. Blood J Am Soc Hematol. 2019;134:548\u201360.","journal-title":"Blood J Am Soc Hematol"},{"key":"2729_CR86","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.stem.2018.07.018","volume":"23","author":"J Sun","year":"2018","unstructured":"Sun J, He X, Zhu Y, Ding Z, Dong H, Feng Y, et al. SIRT1 activation disrupts maintenance of myelodysplastic syndrome stem and progenitor cells by restoring TET2 function. Cell Stem Cell. 2018;23:355\u201369.e359.","journal-title":"Cell Stem Cell"},{"key":"2729_CR87","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/leu.2009.296","volume":"24","author":"A Matsuoka","year":"2010","unstructured":"Matsuoka A, Tochigi A, Kishimoto M, Nakahara T, Kondo T, Tsujioka T, et al. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis. Leukemia. 2010;24:748\u201355.","journal-title":"Leukemia"},{"key":"2729_CR88","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202004079","volume":"220","author":"JA Smolka","year":"2021","unstructured":"Smolka JA, Sanz LA, Hartono SR, Ch\u00e9din F. Recognition of RNA by the S9. 6 antibody creates pervasive artifacts when imaging RNA: DNA hybrids. J Cell Biol. 2021;220:e202004079.","journal-title":"J Cell Biol"},{"key":"2729_CR89","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/s41588-021-00867-2","volume":"53","author":"A Bayona-Feliu","year":"2021","unstructured":"Bayona-Feliu A, Barroso S, Mu\u00f1oz S, Aguilera A. The SWI\/SNF chromatin remodeling complex helps resolve R-loop-mediated transcription\u2013replication conflicts. Nat Genet. 2021;53:1050\u201363.","journal-title":"Nat Genet"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02729-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02729-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02729-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T13:03:03Z","timestamp":1721653383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02729-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,7,22]]}},"alternative-id":["2729"],"URL":"https:\/\/doi.org\/10.1038\/s41416-024-02729-0","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]},"assertion":[{"value":"15 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}